Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.40B P/E - EPS this Y -6.60% Ern Qtrly Grth -
Income -182.39M Forward P/E -11.85 EPS next Y -13.10% 50D Avg Chg -4.00%
Sales - PEG -1.52 EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 3.47 EPS next 5Y 8.90% 52W High Chg -14.00%
Recommedations 1.50 Quick Ratio 23.43 Shares Outstanding 75.43M 52W Low Chg 19.00%
Insider Own 0.38% ROA -15.57% Shares Float 69.56M Beta 1.18
Inst Own 100.09% ROE -22.12% Shares Shorted/Prior 2.62M/2.62M Price 37.79
Gross Margin - Profit Margin - Avg. Volume 337,603 Target Price 58.10
Oper. Margin - Earnings Date May 7 Volume 324,502 Change 1.10%
About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc. News
04/16/24 Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
04/10/24 Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
04/04/24 Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/19/24 Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
03/12/24 Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
03/08/24 Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
03/05/24 Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
03/02/24 Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript
03/01/24 Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
02/29/24 Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results
02/29/24 Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
02/22/24 Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
02/21/24 3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
02/07/24 Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Trading At A 39% Discount?
01/23/24 Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
01/19/24 Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet
01/08/24 Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
01/03/24 Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/04/23 Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/04/23 After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain
XENE Chatroom

User Image Aigner_Andreas Posted - 1 day ago

TD BUY $XENE at 39.50, Supp 39.50 Resis 43.03 R9 HiLo 51% T1Y 51 strong_buy 1.5 DIV N/A #Xenon Phar #stocks #trading #finance #market

User Image perchedcats Posted - 4 days ago

$XENE when will ph3 read out? end of 2024?

User Image Stock_Titan Posted - 1 week ago

$XENE Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-showcases-xen1101-at-the-american-academy-of-10gux8g69gdl.html

User Image Stock_Titan Posted - 2 weeks ago

$XENE Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-to-present-at-the-2024-bloom-burton-co-leam5q8lzwjz.html

User Image Stock_Titan Posted - 3 weeks ago

$XENE Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-to-present-at-the-23rd-annual-needham-virtual-2znqjb90j8gh.html

User Image StockInvest_us Posted - 1 month ago

Signal alert: $XENE - Oversold Trend Short (Undervalued) https://stockinvest.us/l/M4uJmXRlqX

User Image StockInvest_us Posted - 1 month ago

Signal alert: $XENE - PivotPoint bottom https://stockinvest.us/l/XBVp2w0azs

User Image xbibackto70s Posted - 1 month ago

$XENE adding more

User Image Stock_Titan Posted - 1 month ago

$XENE Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-to-present-at-stifel-2024-virtual-cns-sqrlkjbv90x2.html

User Image insiderbuyingselling Posted - 1 month ago

$XENE new insider selling: 2092 shares. http://insiderbuyingselling.com/?t=XENE

User Image xbibackto70s Posted - 1 month ago

$XENE adding little more

User Image xbibackto70s Posted - 1 month ago

$XENE adding little more like this one LT

User Image xbibackto70s Posted - 1 month ago

$XENE added

User Image Stock_Titan Posted - 1 month ago

$XENE Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-to-present-at-leerink-partners-global-g2aj5d2u6v53.html

User Image Estimize Posted - 02/29/24

$XENE beats the Estimize EPS Consensus by 15c and reports inline with the Estimize Revenue Consensus. Reports FQ4 earnings of -64c EPS ... http://www.estimize.com/xene/fq4-2023?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image epsguid Posted - 02/29/24

$XENE reported a loss of $0.64, consensus was ($0.76) via @eWhispers #epsbeat http://eps.sh/d/xene

User Image Stock_Titan Posted - 02/29/24

$XENE Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-ml4zjrcln2ie.html

User Image Estimize Posted - 02/29/24

$XENE reports after the close, Estimize Consensus -0.03 EPS and -2.30M Revs compared to WS http://www.estimize.com/xene/fq4-2023?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image NorthWestHawk Posted - 02/28/24

... By the way, congrats to all that profited when HOOK (first) and then MREO (second) doubled in price after the Nov 18th, 2023 poll (see attached). Clue: Study past Traits they shared with $AXSM, $IDYA, $RYTM, and $XENE that had risen 10X

User Image Stock_Titan Posted - 2 months ago

$XENE Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-e21gxjztj6vx.html

User Image swingingtech Posted - 2 months ago

$XENE, $NVDA, $ARGX, $ITCI https://wallstreetwaves.com/3-biotech-stocks-that-could-be-multibaggers-in-the-making-february-edition/

User Image Quantumup Posted - 2 months ago

RBC🏁 $BHVN OP/$62~is +VE on the way Co identifies promising techs/🎯s--then leverages its Mgmt expertise to optimize the dev path based on comp data2become a fast-follower in high-value Tx areas; believes the mkt can support 2 winning Kv7 modulators, est'g BHV-7000 as having $1B+ pot.. $xene

User Image Quantumup Posted - 2 months ago

UBS initiated🏁 $BHVN Buy/$59 UBS says Biohaven has a "Diversified innovative pipeline with multiple upside drivers;" is bullish on the pipeline and believes Ph1 BHV-1300 (degrader) data in Q1 and Ph3 Spinal muscular atrophy (SMA) readout in the 2H24 are +VE catalysts w/ favorable R/R. $xene

User Image StockConsultant Posted - 2 months ago

$XENE Xenon Pharmaceuticals stock narrow range breakout watch , see https://stockconsultant.com/?XENE

User Image tickeron Posted - 3 months ago

Oh wow this is big! $XENE entered Uptrend as Momentum indicator ascends above 0 level. View odds of downtrend. https://srnk.us/go/4972525

User Image InsiderFinance Posted - 3 months ago

🚨 Heavy institutional volume on $XENE! Options trading 3.6x the daily average, ranking 12 on 🔥 INSIDERFINANCE.IO 🔥 Explore more ➡ @InsiderFinance. Snapshot: - Ticker: $XENE - Momentum Rank: 12 - Volume Surge: 3.6x daily avg 👇 Dive into the options contracts and market analysis in the below screenshot from InsiderFinance's award-nominated trading toolkit.

User Image InsiderFinance Posted - 3 months ago

🚨 Heavy institutional volume on $XENE! Options trading 3.6x the daily average, ranking 12 on 🔥 INSIDERFINANCE.IO 🔥 Explore more ➡ @InsiderFinance. Snapshot: - Ticker: $XENE - Momentum Rank: 12 - Volume Surge: 3.6x daily avg 👇 Dive into the options contracts and market analysis in the below screenshot from InsiderFinance's award-nominated trading toolkit.

User Image ElijahJobs Posted - 3 months ago

$XENE This biotech was just about the only one showing true strength today. I am buying more calls tomorrow. JMO

User Image tickeron Posted - 3 months ago

Good move or bad move? $XENE Stochastic Oscillator left the oversold zone. View odds of downtrend. https://srnk.us/go/4968706

User Image GoddessWen Posted - 3 months ago

$XENE Xene is interesting for 2024. The products are on trend and therapeutics for neurological diseases are attracting a lot of attention. The company has a strong financial position to further develop the pipeline. There are several catalysts in 2024 and Big Pharma is also very interested in companies in this area. https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2024

Analyst Ratings
Needham Buy Apr 12, 24
Cantor Fitzgerald Overweight Apr 10, 24
RBC Capital Outperform Mar 1, 24
Wedbush Outperform Mar 1, 24
Needham Buy Mar 1, 24
Citigroup Buy Jan 4, 24
B of A Securities Buy Jan 2, 24
Stifel Buy Dec 18, 23
Baird Outperform Dec 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
AZAB MOHAMMAD Director Director Dec 19 Option 9.85 4,320 42,552 74,225 12/20/23
PATOU GARY Director Director Dec 13 Sell 41.05 7,598 311,898 4,902 12/15/23
PATOU GARY Director Director Dec 13 Option 9.57 14,402 137,827 28,717 12/15/23
Svoronos Dawn Director Director Aug 24 Sell 38.70 25,000 967,500 25,000 08/24/23
PIMSTONE SIMON N. Director Director May 30 Sell 38.9 131,245 5,105,430 6,000 06/01/23
PIMSTONE SIMON N. Director Director May 30 Option 13.27 134,153 1,780,210 51,000 06/01/23
MORTIMER IAN PRESIDENT & CEO PRESIDENT & CEO May 24 Sell 41.43 31,655 1,311,467 31,302 05/26/23
MORTIMER IAN PRESIDENT & CEO PRESIDENT & CEO May 24 Option 9.71 69,340 673,291 33,880 05/26/23
KENNEY CHRISTOPHER JOHN Chief Medical Office.. Chief Medical Officer Mar 24 Sell 35.01 700 24,507 03/24/23
PIMSTONE SIMON N. Director Director Mar 07 Sell 36.98 19,232 711,199 55,006 03/09/23
PIMSTONE SIMON N. Director Director Mar 07 Option 2.64 72,016 190,122 64,866 03/09/23
PATOU GARY Director Director Nov 23 Option 2.68 2,057 5,513 25,630 11/28/22
PATOU GARY Director Director Nov 23 Sell 34.56 3,994 138,033 23,573 11/28/22
EMPFIELD JAMES R. EVP, Drug Discovery EVP, Drug Discovery Aug 12 Option 3.93 65,000 255,450 75,000 08/16/22
EMPFIELD JAMES R. EVP, Drug Discovery EVP, Drug Discovery Aug 12 Sell 38.38 57,743 2,216,176 10,000 08/16/22
PIMSTONE SIMON N. Director Director Aug 12 Sell 38.43 177,135 6,807,298 6,000 08/16/22
PIMSTONE SIMON N. Director Director Mar 04 Sell 30.80 2,500 77,000 193,135 03/08/22
PIMSTONE SIMON N. Director Director Mar 04 Option 3.67 30,864 113,271 230,762 03/08/22
ROBIN SHERRINGTON EVP, Strategy & Inno.. EVP, Strategy & Innovation Mar 04 Option 3.67 7,406 27,180 38,942 03/08/22
ROBIN SHERRINGTON EVP, Strategy & Inno.. EVP, Strategy & Innovation Mar 04 Sell 30.5 21,710 662,155 17,232 03/08/22
EMPFIELD JAMES R. EVP, Drug Discovery EVP, Drug Discovery Mar 04 Option 7.85 67,500 529,875 51,805 03/08/22
EMPFIELD JAMES R. EVP, Drug Discovery EVP, Drug Discovery Mar 04 Sell 30.65 51,168 1,568,299 10,000 03/08/22
KENNEY CHRISTOPHER JOHN Chief Medical Office.. Chief Medical Officer Jan 21 Buy 28.81 700 20,167 700 01/21/22